CM
ADPT icon

Castleark Management’s Adaptive Biotechnologies ADPT Stock Holding History

Castleark Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-390,874
Closed -$6.35M – 293
2025
Q4 		$6.35M Buy
390,874
+92,800
+31% +$1.51M 0.19% 134
2025
Q3 		$4.46M Buy
+298,074
New +$3.63M 0.13% 153

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Castleark Management's ADPT Position: Q1 2026 in Review

Castleark Management sold out of Adaptive Biotechnologies (ADPT) in Q1 2026, closing a stake of 390,874 shares — an estimated $6.35M sold.

Castleark Management first reported a position in ADPT in Q3 2025 and held it in 2 quarters. The position peaked at $6.35M in Q4 2025. 298 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Castleark Management reported no remaining Adaptive Biotechnologies position as of Q1 2026 after selling out during the quarter.
  • Castleark Management sold 390,874 Adaptive Biotechnologies shares in Q1 2026, an estimated $6.35M.
  • Castleark Management first reported a position in Adaptive Biotechnologies in Q3 2025 and held it in 2 quarters.
  • Castleark Management's Adaptive Biotechnologies position peaked at $6.35M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Castleark Management's 13F filing for Q1 2026, filed 15 May 2026.